Going on Trial: Gene therapy for Rett; return to arbaclofen
This month’s newsletter looks at the early safety data from the first gene therapy trial for Rett syndrome, among other drug development news.
This month’s newsletter looks at the early safety data from the first gene therapy trial for Rett syndrome, among other drug development news.
The results lend support for clinical trials of arbaclofen in people with an autism-linked condition, the researchers say.
A careful clinician who prizes evidence, Jeremy Veenstra-VanderWeele is happy to embrace trial failures, as long as he learns from them.
New data from clinical trials of arbaclofen and oxytocin underscore the murkiness of null results. Plus, researchers seek clarity on the neurodevelopmental effects of oxytocin during childbirth.
Autistic children taking the drug showed improvements in some behaviors but not in their social skills.
Going on Trial rounds up new developments in autism-related drug trials. This month we’re revisiting decade-old data from a trial of arbaclofen for fragile X syndrome and looking into a new implant-based approach to quelling seizures, among other treatment strategies.
The investigational drug arbaclofen makes autistic people’s brains respond to a visual task more like non-autistic people’s brains do.
A test of binocular rivalry may distinguish between autism subtypes and help researchers screen the efficacy of certain drugs.
A brain region that orchestrates responses to social cues and aids decision-making may be off tempo in autism.
New results from brain scans of adults with autism are at odds with the popular theory that the condition involves weak brakes on brain activity.